Table 3 Agreement rates between detecting clinical samples using the commercial kit and the method developed in this study
| Â | Â | Commercial kit | Agreement rate | ||
|---|---|---|---|---|---|
Positive | Negative | Total | |||
PEDV | |||||
The method developed in this study | Positive | 30 | 1 | 31 | 97.5% |
Negative | 1 | 48 | 49 | ||
Total | 31 | 49 | 80 | ||
TGEV | |||||
The method developed in this study | Positive | 17 | 3 | 20 | 95.0% |
Negative | 1 | 59 | 60 | ||
Total | 18 | 62 | 80 | ||
RVA | |||||
The method developed in this study | Positive | 27 | 10 | 37 | 86.3% |
Negative | 1 | 42 | 43 | ||
Total | 29 | 51 | 80 | ||
PDCoV | |||||
The method developed in this study | Positive | 32 | 1 | 33 | 98.8% |
Negative | 0 | 47 | 47 | ||
Total | 32 | 48 | 80 | ||